CAN:s bibliotek

*000      am a        a
*00116865
*007cr |||||||||||
*008070120s1995||||xxu||||es|||||||||1|eng||
*24510$aMedications development for the treatment of pregnant addicts and their infants.
*260  $aRockville, Md :$bNational Institute on Drug Abuse,$c1995
*300  $a246 s.
*440  $aNIDA research monograph series ;$v149
*440  $aNIH publication ;$v95-3891
*500  $aE-bok
*520  $aOverview: medications development for the treatment of drug abuse. Overview of the effects of abuse and drugs on pregnancy and offspring. Clinical management of drug dependency in pregnancy. Methadone use during pregnancy. Treatment options for drug-exposed infants. Opioid receptor approaches for the development of medications for pregnant women. Pharmacokinetic and pharmacodynamic considerations for the design and screening of potential medications. The application of the principles of toxicology and teratology in evaluating the risks of new drugs for the treatment of drug addiction in women of reproductive age. Drug delivery systems: possible applications in the treatment of drug addiction. Clinical trials of pharmacologic treatments in pregnant women - methodologic considerations. Legal and ethical issues. Testing medications for the treatment of addiction in pregnancy: one reviewer's opinion.
*650 4$aDrug therapy
*650 4$aFemale
*650 4$aPregnancy
*650 4$aMethadone
*650 4$aEthics
*650 4$aAbstinence syndrome, neonatal
*650 4$aClinical Trials
*653  $aFarmakoterapi
*653  $aKvinnor
*653  $aMetadon
*653  $aGraviditet
*653  $aNyfödda
*653  $aAbstinens
*653  $aEtik
*7001 $aChiang, C. Nora$eed.
*7001 $aFinnegan, Loretta, P.$eed.
*7101 $aNational Institute on Drug Abuse$0124050
*85640$uhttps://archives.drugabuse.gov/sites/default/files/monograph149.pdf
^